ATE494373T2 - Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle - Google Patents

Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle Download PDF

Info

Publication number
ATE494373T2
ATE494373T2 AT05749437T AT05749437T ATE494373T2 AT E494373 T2 ATE494373 T2 AT E494373T2 AT 05749437 T AT05749437 T AT 05749437T AT 05749437 T AT05749437 T AT 05749437T AT E494373 T2 ATE494373 T2 AT E494373T2
Authority
AT
Austria
Prior art keywords
target cell
methods
compositions
hcv virus
reducing amounts
Prior art date
Application number
AT05749437T
Other languages
English (en)
Inventor
Peter Sarnow
Catherine Jopling
Alissa Lancaster
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494373(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE494373T2 publication Critical patent/ATE494373T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT05749437T 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle ATE494373T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56835804P 2004-05-04 2004-05-04
PCT/US2005/015264 WO2005107816A2 (en) 2004-05-04 2005-05-03 Methods and compositions for reducing viral genome amounts in a target cell

Publications (1)

Publication Number Publication Date
ATE494373T2 true ATE494373T2 (de) 2011-01-15

Family

ID=35320743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05749437T ATE494373T2 (de) 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle

Country Status (15)

Country Link
US (6) US7307067B2 (de)
EP (3) EP2500431A3 (de)
JP (2) JP4943322B2 (de)
AT (1) ATE494373T2 (de)
AU (1) AU2005240118C1 (de)
CA (2) CA2912903A1 (de)
CY (1) CY1111755T1 (de)
DE (1) DE602005025751D1 (de)
DK (1) DK1747023T4 (de)
ES (1) ES2361458T5 (de)
IL (1) IL178679B (de)
PL (1) PL1747023T5 (de)
PT (1) PT1747023E (de)
SI (1) SI1747023T1 (de)
WO (1) WO2005107816A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
EP1793674B1 (de) * 2003-11-26 2018-05-30 University of Massachusetts Sequenzspezifische hemmung der funktion von kleiner rna
PT1747023E (pt) * 2004-05-04 2011-04-11 Univ Leland Stanford Junior Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
EP2290073A3 (de) 2004-05-28 2011-08-31 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006113431A2 (en) * 2005-04-13 2006-10-26 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1919512B1 (de) * 2005-08-10 2014-11-12 Alnylam Pharmaceuticals Inc. Chemisch modifizierte oligonukleotide zur verwendung bei der modulierung von mikro-rna und ihre verwendungen
WO2007027775A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
US7516342B2 (en) 2005-12-30 2009-04-07 Intel Corporation Method, apparatus and system to dynamically choose an optimum power state
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (de) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmazeutische Zusammensetzung mit Anti-miRNA-Antisense-Oligonukleotiden
CA2663878A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
JP5149528B2 (ja) * 2007-03-30 2013-02-20 学校法人東京医科大学 Ｃ型肝炎ウイルスの複製を制御するマイクロｒｎａ
WO2009029681A2 (en) * 2007-08-27 2009-03-05 The Regents Of The University Of California Micrornas for inhibiting viral replication
EP2198050A1 (de) 2007-09-14 2010-06-23 Asuragen, INC. Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
EP2268811A1 (de) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
EP3067359A1 (de) 2008-09-23 2016-09-14 Scott G. Petersen Selbstfreisetzende biolabile phosphatgeschützte pro-oligos für therapeutika auf oligonukleotidbasis und vermittlung von rna-interferenz
EP2191834A1 (de) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Zusammensetzungen und Verfahren zur Behandlung von Retrovireninfektionen
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
EP2558578B1 (de) 2010-04-13 2015-10-28 Life Technologies Corporation Zusammensetzungen und verfahren zur hemmung der funktion von nukleinsäuren
DK2561078T3 (en) 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
EP2663323B1 (de) 2011-01-14 2017-08-16 The General Hospital Corporation Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2992095B1 (de) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Microrna-verbindungen und verfahren zur modulation von mir-122
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
EP3198012B1 (de) 2014-09-26 2019-09-04 University of Massachusetts Rna-modulierende stoffe
EP3218485A1 (de) 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Lang wirkende pharmazeutische zusammensetzungen für hepatitis c
SG11201703646SA (en) 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3790972A1 (de) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac-konjugiertes modifiziertes oligonucleotid als mir-122-inhibitor mit hcv-antiviraler aktivität mit reduzierter hyperbilirubinämischer nebenwirkung
CN111904973B (zh) * 2020-07-27 2021-12-03 中国农业科学院兰州兽医研究所 ssc-miR-122在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
JPH06311885A (ja) † 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
US6423489B1 (en) † 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
JPH10503364A (ja) † 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0877600B1 (de) 1996-08-09 2003-10-22 Alcon Manufacturing Ltd. Konservierungssysteme fur cyclodextrine enthaltende arzneimittel
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
EP1383782A1 (de) * 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonukleotidvermittelte inhibierung der replikation des hepatitis--b-virus und des hepatitis-c-virus
FR2830254B1 (fr) * 2001-09-28 2004-09-17 Synkem Nouvelles diphosphines, leurs complexes avec des metaux de transition et leur utilisation en synthese asymetrique
CA2462144C (en) * 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
CN1768139A (zh) * 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
MXPA05008106A (es) * 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US20070270361A1 (en) 2003-08-04 2007-11-22 Shan Lu Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
WO2005013905A2 (en) 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
EP1793674B1 (de) * 2003-11-26 2018-05-30 University of Massachusetts Sequenzspezifische hemmung der funktion von kleiner rna
PT1747023E (pt) * 2004-05-04 2011-04-11 Univ Leland Stanford Junior Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2011000092A1 (en) 2009-06-29 2011-01-06 Matthew Hunsberger A disc brake for a tape measure

Also Published As

Publication number Publication date
PL1747023T3 (pl) 2011-08-31
EP1747023B2 (de) 2016-03-09
AU2005240118A1 (en) 2005-11-17
AU2005240118C1 (en) 2014-02-13
CA2912903A1 (en) 2005-11-17
PL1747023T5 (pl) 2017-05-31
DE602005025751D1 (de) 2011-02-17
US7838504B2 (en) 2010-11-23
US8759312B2 (en) 2014-06-24
DK1747023T4 (en) 2016-05-02
DK1747023T3 (da) 2011-04-18
AU2005240118B2 (en) 2011-09-08
ES2361458T3 (es) 2011-06-17
JP4943322B2 (ja) 2012-05-30
EP2500431A3 (de) 2013-12-18
CA2564503C (en) 2015-12-29
US20150005362A1 (en) 2015-01-01
WO2005107816A2 (en) 2005-11-17
EP2338996A2 (de) 2011-06-29
EP2338996A3 (de) 2013-12-18
EP1747023A2 (de) 2007-01-31
JP5602123B2 (ja) 2014-10-08
JP2012102116A (ja) 2012-05-31
US7307067B2 (en) 2007-12-11
US8217020B2 (en) 2012-07-10
PT1747023E (pt) 2011-04-11
IL178679B (en) 2019-01-31
US20080234220A1 (en) 2008-09-25
SI1747023T1 (sl) 2011-06-30
ES2361458T5 (es) 2016-04-20
EP1747023A4 (de) 2010-03-03
EP1747023B1 (de) 2011-01-05
CY1111755T1 (el) 2015-10-07
CA2564503A1 (en) 2005-11-17
JP2007536242A (ja) 2007-12-13
US20110124707A1 (en) 2011-05-26
US9416362B2 (en) 2016-08-16
EP2500431A2 (de) 2012-09-19
US20120329856A1 (en) 2012-12-27
IL178679A0 (en) 2007-02-11
WO2005107816A3 (en) 2006-02-23
US20050288245A1 (en) 2005-12-29
US20160348116A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
DE602005025751D1 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200700243A1 (ru) Способы лечения гепатита с
WO2011123645A3 (en) Nucleoside phosphoramidates
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007084413A3 (en) Methods for treating hepatitis c
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2007095269A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2008085508A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
DE602006015861D1 (de) Antivirale verbindungen
NO20090453L (no) Hepatitt C Virusinhibitorer
WO2010047830A3 (en) Agents for hcv treatment
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2008133753A3 (en) Anti-viral compounds
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
BRPI0811633A2 (pt) compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
EP2399575A3 (de) Verfahren, Verwendungen und Zusammensetzungen zur Behandlung einer Infektion durch einen Virus aus der Familie der Flaviviridae durch Hemmung des Farnesoid X-Rezeptors (FXR)
WO2007084435A3 (en) Methods for treating hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1747023

Country of ref document: EP